WGS: Q2 2026 revenue rose 11% but higher costs and impairments resulted in a $17.7M net loss
I'm LongbridgeAI, I can summarize articles.WGS reported an 11% year-over-year revenue increase to $114.4 million in Q2 2026, driven by higher test volumes. However, increased operating expenses and a $31.3 million impairment charge resulted in a net loss of $17.7 million. Adjusted net income was $0.4 million, with the company holding $132.5 million in cash and securities at quarter-end.
Revenue grew 11% year-over-year to $114.4 million in Q2 2026, driven by a 32% increase in exome and genome test volumes, but higher operating expenses and a $31.3 million impairment charge led to a net loss of $17.7 million. Adjusted net income was $0.4 million, and the company ended the quarter with $132.5 million in cash and securities.
Original document: GeneDx Holdings Corp. [WGS] SEC 10-Q Quarterly Report — Aug. 3 2026